These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 10408002)

  • 1. [Pharmacology of HMG CoA reductase inhibitors (statins)].
    Kostner GM
    Wien Med Wochenschr; 1999; 149(5-6):120-4. PubMed ID: 10408002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin.
    Conde K; Pineda G; Newton RS; Fernandez ML
    Biochem Pharmacol; 1999 Oct; 58(7):1209-19. PubMed ID: 10484079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production.
    Roglans N; Verd JC; Peris C; Alegret M; Vázquez M; Adzet T; Díaz C; Hernández G; Laguna JC; Sánchez RM
    Lipids; 2002 May; 37(5):445-54. PubMed ID: 12056585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atorvastatin: pharmacological characteristics and lipid-lowering effects.
    Poli A
    Drugs; 2007; 67 Suppl 1():3-15. PubMed ID: 17910517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin.
    Naoumova RP; Dunn S; Rallidis L; Abu-Muhana O; Neuwirth C; Rendell NB; Taylor GW; Thompson GR
    J Lipid Res; 1997 Jul; 38(7):1496-500. PubMed ID: 9254075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pleiotropic effects of statins].
    Mennickent C S; Bravo D M; Calvo M C; Avello L M
    Rev Med Chil; 2008 Jun; 136(6):775-82. PubMed ID: 18769836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insights into the pharmacodynamic and pharmacokinetic properties of statins.
    Corsini A; Bellosta S; Baetta R; Fumagalli R; Paoletti R; Bernini F
    Pharmacol Ther; 1999 Dec; 84(3):413-28. PubMed ID: 10665838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
    McKenney JM
    Am J Cardiol; 2005 Aug; 96(4A):60E-66E. PubMed ID: 16098846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid-lowering response to statins is affected by CYP3A5 polymorphism.
    Kivistö KT; Niemi M; Schaeffeler E; Pitkälä K; Tilvis R; Fromm MF; Schwab M; Eichelbaum M; Strandberg T
    Pharmacogenetics; 2004 Aug; 14(8):523-5. PubMed ID: 15284534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.
    Mazza F; Stefanutti C; Di Giacomo S; Vivenzio A; Fraone N; Mazzarella B; Bucci A
    Am J Cardiovasc Drugs; 2008; 8(4):265-70. PubMed ID: 18690760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor.
    Stern RH; Yang BB; Hounslow NJ; MacMahon M; Abel RB; Olson SC
    J Clin Pharmacol; 2000 Jun; 40(6):616-23. PubMed ID: 10868312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS; Goa KL
    Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physicochemical modifications induced by statins therapy on human erythrocytes membranes.
    Broncel M; Bała A; Koter-Michalak M; Duchnowicz P; Wojsznis W; Chojnowska-Jezierska J
    Wiad Lek; 2007; 60(7-8):321-8. PubMed ID: 18175550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical relevance of low-density-lipoproteins size modulation by statins.
    Rizzo M; Berneis K
    Cardiovasc Drugs Ther; 2006 Jun; 20(3):205-17. PubMed ID: 16775666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells.
    Ishikawa M; Okajima F; Inoue N; Motomura K; Kato T; Takahashi A; Oikawa S; Yamada N; Shimano H
    J Atheroscler Thromb; 2006 Dec; 13(6):329-35. PubMed ID: 17192698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors.
    Alfon J; Guasch JF; Berrozpe M; Badimon L
    Atherosclerosis; 1999 Aug; 145(2):325-31. PubMed ID: 10488960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
    Pedersen TR
    Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.